BIODESIX INC (BDSX) Form 10-Q — May 4, 2026

$BDSXForm 10-QFiled May 4, 2026, 4:05 PM ET0001193125-26-203960Original filing

Biodesix reported first quarter 2026 revenue of $25.6 million, a 42% increase from the prior year, driven by growth in both Diagnostic Testing and Development Services revenue. The company narrowed its net loss to $7.8 million compared to $11.1 million in the prior year period, supported by improved gross margins and operating leverage. During the quarter, Biodesix raised approximately $17.2 million in gross proceeds through its at-the-market equity program, ending the period with $25.6 million in cash and cash equivalents.

Key figures

Eps: -0.81
Revenue: 25555000
Total Debt: 46489000
Revenue Yoy: 42%
Cash Position: 25572000
Shares Outstanding: 10108580

Price after filing

1 day: +32.6%7 days: +42.9%30 days: +42.9%

Close on the filing date to close N calendar days later (from $11.27). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.